

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 August 2002 (15.08.2002)

(10) International Publication Number
PCT
WO 02/062324 A2

- (51) International Patent Classification⁷: **A61K 31/00**,
A61P 1/06
- (21) International Application Number: PCT/GB02/00310
- (22) International Filing Date: 24 January 2002 (24.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0102854.7 5 February 2001 (05.02.2001) GB
0102855.4 5 February 2001 (05.02.2001) GB
0102856.2 5 February 2001 (05.02.2001) GB
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant and
(72) Inventor: **KAMM, Michael, Albert** [AU/GB]; 4
Willoughby Road, Hampstead, London NW3 1SA (GB).
- (74) Agent: **BURFORD, Anthony, F.**; W. H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/062324 A2

(54) Title: A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-OESOPHAGEAL REFLUX DISEASE

(57) Abstract: Smooth muscle one modulators are applied topically to treat oesophageal motility disorders and gastro-oesophageal reflux disease. Topical application of the smooth muscle tone modulators reduces the risk of the unwanted side-effects observed from oral or sublingual administration of the modulators.

A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-
OESOPHAGEAL REFLUX DISEASE

5 The present invention relates to the use of a smooth muscle tone modulator in the manufacture of a medicament for use in the topical treatment of oesophageal motility disorders and gastro-oesophageal reflux disease ("GORD"). In particular, the invention relates to the use of a smooth muscle relaxant in the manufacture of a medicament for use in the topical treatment of oesophageal
10 spasm, nutcracker oesophagus, non-specific oesophageal motility disorder, and other disorders of oesophageal body dysmotility and in the topical treatment of achalasia and hypertensive lower oesophageal sphincter ("LOS") and to the use of a smooth muscle contraction stimulant (or "contractant") in the manufacture of a medicament for use in the topical treatment of GORD.

15 The term "smooth muscle tone modulator" includes any pharmacologically-acceptable compound which regulates and/or adjusts smooth muscle tone and embraces smooth muscle relaxants and smooth muscle contractants. A smooth muscle relaxant includes agents that either decrease smooth muscle tone or
20 prevent smooth muscle contraction and agents that have both of these activities. A smooth muscle contractant includes agents that either increase smooth muscle tone or prevent smooth muscle relaxation and agents that have both of these activities.

25 Normal oesophageal function is dependent on the integration of normal extrinsic nerve, intrinsic nerve and muscle functions. When oesophageal neuromuscular function is abnormal, a number of symptoms and clinical disorders can result. If there is a failure of normal peristalsis, food and liquid may fail to be propelled into the stomach, with the resultant sensation of blockage, pain and the
30 regurgitation of food. This can happen without obvious cause, or can occur in association with recognised syndromes. One such recognised syndrome is diffuse oesophageal spasm which is a condition in which there is a failure of

propagated peristalsis, with simultaneous contraction of oesophageal muscle along the length of the oesophagus. An extreme example of this condition is known as cork-screw oesophagus, in which there are high pressure segmenting non-propagating contractions of the oesophageal body. A further example is
5 nutcracker oesophagus which is a condition in which peristaltic propagated contractions are preserved, but in which the oesophageal muscle contracts excessively strongly. This results in high pressure contractions which can result in pain for the sufferer.

10 In some patients, there is a non-specific disorder of oesophageal function that has the features of oesophageal spasm and nutcracker oesophagus in conjunction with the features of a different condition known as achalasia which is a condition in which there is a failure of propagated contractions in the body of the oesophagus associated with a high resting tone in the LOS and failure of LOS
15 relaxation on swallowing.

There is a separate condition in which the resting pressure in the LOS is increased, i.e. sphincter tone is increased above normal. Such a condition may be present without the other features of achalasia, so that the muscle may relax fully
20 or partly on swallowing, and motility in the body of the oesophagus is not abnormal. This condition is known as hypertensive LOS.

The oesophageal body receives both an extrinsic (cholinergic parasympathetic) innervation and an intrinsic innervation. The traditional
25 treatment of oesophageal motility disorders resulting from abnormal oesophageal neuromuscular function has relied on the use of oral (including sublingual) medication in the form of tablets or sprays comprising calcium channel blockers and nitric oxide ("NO") donors, e.g. glyceryl trinitrate. However, all of these medications mediate their effect through a systemic mechanism, after absorption
30 from the gastro-intestinal ("GI") tract into the blood stream. They are only moderately effective and suffer the problem of systemic side effects such as

headaches and reduced blood pressure. Surgical myotomy has also been used although this treatment is inconvenient and painful for the sufferer.

5 The smooth muscle LOS receives both an extrinsic (noradrenergic and cholinergic parasympathetic) innervation and an intrinsic innervation. The extrinsic excitatory innervation consists of a sympathetic alpha-1 adrenergic innervation which is partly responsible for the maintenance of LOS tone. The extrinsic cholinergic parasympathetic innervation causes LOS relaxation. The sphincter receives further inhibitory extrinsic innervation which is beta-adrenergic, 10 and possibly also involves alpha-2 effects. The sphincter also receives an innervation involving other neurotransmitters such as nitric oxide ("NO"), ATP, GABA and prostaglandins.

15 Traditional treatments of achalasia and hypertensive LOS include forceful or pneumatic dilation of the LOS with a dilating instrument. This is inconvenient for the sufferer and dilation usually has to be repeated. Oral (including sublingual) administration of NO donors and calcium channel blockers in the form of tablets or sprays has also been used. However, these treatments mediate their effect through a systemic mechanism, after absorption from the GI tract into the blood 20 stream. They are only moderately effective, and suffer the problem of systemic side effects such as headaches and reduced blood pressure.

25 The traditional treatment of GORD depends on the severity of the condition. Mild cases are treatable by simply elevating the head of the sufferer when the sufferer is lying down, by dietary control and by taking antacids after meals and at bedtime. More severe cases are treated by reducing the level of gastric acid production using histamine type 2 ("H2") blockers or proton pump inhibitors taken orally. Recently, there has been interest in developing systemically active drugs which modulate the neural control of the LOS, 30 preventing excessive relaxations. Oral treatment is mediated by a systemic mechanism which gives rise to unwanted side effects such as headaches.

WO-A-87/04077 (Martin *et al*) discloses a pharmaceutical composition comprising a local anaesthetic adapted to inhibit relaxation of the LOS and a carrier therefor comprising a material adapted to float on gastrointestinal fluids contained in the stomach. The composition is designed to place the local
5 anaesthetic in contact with the LOS or the gastric mucosa near the LOS. In the preferred embodiment, the composition comprises GAVISCON™ as the carrier. GAVISCON™ is produced by Reckitt & Coleman and described in US-A-4140760.

According to a first aspect of the present invention, there is provided use of
10 a smooth muscle tone modulator in the manufacture of a medicament for the topical treatment of oesophageal motility disorders and GORD.

When applied topically to the oesophagus, LOS and stomach lining, a high concentration of a smooth muscle tone modulator may be administered for local
15 effect thereby avoiding systemic side effects. The modulator is not absorbed systemically and, if it is passed into the small bowel, it is absorbed and inactivated by the normal mechanisms of drug metabolism such as in the liver.

The medicament is suitable for application to the oesophagus, LOS and
20 stomach lining as required and is preferably mucoadhesive. A mucoadhesive medicament is more resistant to being removed from the oesophageal wall or LOS than a non-mucoadhesive medicament. Prolonged contact of the medicament with the oesophageal body, LOS and stomach lining in this way improves the level of absorption or "uptake" of the smooth muscle tone modulator
25 across the mucosal membrane of the oesophagus (i.e. the epithelium) or stomach or into the LOS when compared to that for a non-mucoadhesive medicament.

Preferably, the medicament is in the form of a solution, an emulsion, a gel or a foam that is swallowed by the sufferer. The medicament may comprise a
30 polymeric matrix.

The smooth muscle tone modulator may be present in the medicament in a concentration of from 0.01 to 40 wt %.

5 A first preferred embodiment involves the use of a smooth muscle relaxant in the manufacture of a medicament for use in the topical treatment of oesophageal spasm, nutcracker oesophagus, non-specific oesophageal motility disorder, and other oesophageal body dysmotility syndromes.

10 A second preferred embodiment involves the use of a smooth muscle relaxant in the manufacture of a medicament for use in the topical treatment of achalasia and hypertensive LOS.

The smooth muscle relaxant may be a calcium channel blocker (e.g. diltiazem or nifedipine), a potassium channel opener, a nitric oxide donor (e.g. 15 glyceryl trinitrate, isosorbide trinitrate, L-arginine, S-nitroso-N-acetylpenicillamine or nitroprusside), an adrenergic agonist (e.g. phenylephrine), a beta agonist (including a beta-2 agonist or a beta-3 agonist), a dopaminergic agonist, a prostaglandin modifier, a GABA antagonist, a glutamate antagonist, a tachykinin antagonist, capsaicin, dicyclomine or flavoxate. In addition, the relaxant may be 20 an alpha-1 adrenergic antagonist (e.g. prazosin, phenoxybenzamide, dibenamide, doxazosin, terazosin, phentolamine, tolazoline or trimazosin), a cholinergic agent or anticholinesterase, a cholinergic agonist or a cholinomimetic agent (e.g. bethanechol). In the case of oesophageal body disorders in which there is excessive neuromuscular action, the smooth muscle relaxant may also be an 25 anticholinergic agent (e.g. atropine or hyoscine).

A third preferred embodiment involves the use of a smooth muscle contractant in the manufacture of a medicament for use in the topical treatment of GORD.

30

The medicament of the third preferred embodiment may form a "raft" that floats on the surface of the stomach contents thereby not only placing the smooth

muscle contractant in contact with the mucosal membrane of the stomach (preferably near the LOS) but also physically obstructing gastric reflux. For example, the medicament may comprise a bicarbonate compound that reacts with gastric acid to form carbon dioxide which helps foam the medicament.

5

The smooth muscle contractant may be an alpha-1 adrenergic agonist (e.g. phenylephrine), an anticholinergic agent (e.g. atropine, propantheline, emepronium, trospium, tolteridone, darifenacin, oxybutinin or hyoscine), a nitric oxide synthase ("NOS") antagonist (e.g. L-NAME), a prostaglandin modifier, a
10 GABA agonist (e.g. baclofen), a tricyclic antidepressant (e.g. imipramine or amitryptaline), a noradrenaline and serotonin uptake inhibitor (e.g. duloxetine), a serotonin agonist or antagonist, an opioid analogue, a dopaminergic antagonist, a beta-antagonist (including beta-2 and beta-3 antagonists), glutamate (or a related agonist) or a tachykinin antagonist.

15

The medicament may comprise an antacid.

According to a second aspect of the present invention, there is provided use of a composition comprising a smooth muscle tone modulator and a
20 therapeutically acceptable mucoadhesive vehicle in the manufacture of a medicament for the topical treatment of oesophageal motility disorders and GORD. The term "therapeutically acceptable mucoadhesive vehicle" includes a mucoadhesive vehicle that is pharmacologically acceptable.

25

A first preferred embodiment of the second aspect involves the use of a composition comprising a smooth muscle relaxant and a therapeutically acceptable vehicle in the manufacture of a medicament for use in the topical treatment of oesophageal spasm, nutcracker oesophagus, non-specific oesophageal motility disorder, and other oesophageal body dysmotility
30 syndromes.

A second preferred embodiment of the second aspect involves the use of a composition comprising a smooth muscle relaxant and a therapeutically acceptable vehicle in the manufacture of a medicament for use in the topical treatment of achalasia and hypertensive LOS.

5

A third preferred embodiment of the second aspect involves the use of a composition comprising smooth muscle contractant and a therapeutically acceptable vehicle in the manufacture of a medicament for use in the topical treatment of GORD.

10

The medicament of the preferred embodiments may be as defined above.

According to a third aspect of the present invention, there is provided a method of treating oesophageal motility disorders and GORD comprising administering topically a pharmaceutically acceptable amount of a smooth muscle tone modulator to the upper GI tract which includes the oesophagus, the LOS and the stomach.

According to fourth aspect of the present invention, there is provided a method of treating a condition selected from the group consisting of oesophageal spasm, nutcracker oesophagus, non-specific oesophageal motility disorder and other disorders of oesophageal dysmotility comprising administering topically a pharmaceutically acceptable amount of a smooth muscle relaxant to the upper GI tract, particularly the oesophagus and the LOS.

25

According to a fifth aspect of the present invention, there is provided a method of treating achalasia and hypertensive LOS comprising administering topically a pharmaceutically acceptable amount of a smooth muscle relaxant to the upper GI tract, particularly the oesophagus and the LOS.

30

According to a sixth aspect of the present invention, there is provided a method of treating GORD comprising administering topically a pharmaceutically

acceptable amount of a smooth muscle contractant to the upper GI tract, particularly the LOS and the stomach.

- It will be appreciated that the invention is not restricted to the details
- 5 described above with reference to the preferred embodiments but that numerous modifications and variations can be made without departing from the scope of the invention as defined in the following claims.

CLAIMS

1. Use of a smooth muscle tone modulator in the manufacture of a medicament for use in the topical treatment of oesophageal motility disorders
5 and gastro-oesophageal reflux disease ("GORD").
2. Use as claimed in Claim 1, wherein the medicament is mucoadhesive.
3. Use as claimed in Claim 1 or Claim 2, wherein the medicament is in a
10 swallowable form selected from solution, emulsion, gel or foam.
4. Use as claimed in any one of Claims 1 to 3, wherein the smooth muscle tone modulator is a smooth muscle relaxant and the medicament is for use in the topical treatment of oesophageal spasm, nutcracker oesophagus, non-specific
15 oesophageal motility disorder, and other oesophageal body dysmotility syndromes.
5. Use as claimed in any one of Claims 1 to 3, wherein the smooth muscle tone modulator is a smooth muscle relaxant and the medicament is for use in the
20 topical treatment of achalasia and hypertensive lower oesophageal sphincter ("LOS").
6. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a calcium channel blocker.
25
7. Use as claimed in Claim 6, wherein the calcium channel blocker is diltiazem or nifedipine.
8. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle
30 relaxant is a potassium channel opener.
9. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a nitric oxide donor.

10. Use as claimed in Claim 9, wherein the nitric oxide donor is glyceryl trinitrate, isosorbide trinitrate, L-arginine, S-nitroso-N-acetylpenicillamine or nitroprusside.
5. 11. Use as claimed in Claim 4 of Claim 5, wherein the smooth muscle relaxant is an adrenergic agonist.
- 10 12. Use as claimed in Claim 11, wherein the adrenergic agonist is phenylephrine.
13. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a beta agonist, a beta-2 agonist or a beta-3 agonist.
- 15 14. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a dopaminergic agonist.
- 15 15. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a prostaglandin modifier.
- 20 16. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a GABA antagonist.
- 25 17. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a glutamate antagonist.
18. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a tachykinin antagonist.
- 30 19. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is capsaicin, dicyclomine or flavoxate.

20. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is an anticholinergic agent.

21. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle
5 relaxant is an alpha-1 adrenergic antagonist.

22. Use as claimed in Claim 21, wherein the alpha-1 adrenergic antagonist is prazosin, phenoxybenzamide, dibenamide, doxazosin, terazosin, phentolamine, tolazoline or trimazosin.

10

23. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a cholinergic agent or anticholinesterase.

24. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle
15 relaxant is a cholinergic agonist.

25. Use as claimed in Claim 4 or Claim 5, wherein the smooth muscle relaxant is a cholinomimetic agent.

20 26. Use as claimed in Claim 25, wherein the cholinomimetic agent is bethanechol.

27. Use as claimed in any one of Claims 1 to 3, wherein the smooth muscle tone modulator is a smooth muscle contractant and the medicament is for use in
25 the topical treatment of GORD.

28. Use as claimed in Claim 27, wherein the medicament is used in a swallowable form that forms a raft that floats on the surface of the contents of the stomach.

30

29. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is an alpha-1 adrenergic agonist.

30. Use as claimed in Claim 29, wherein the alpha-1 adrenergic agonist is phenylephrine.

31. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle
5 contractant is an anticholinergic agent.

32. Use as claimed in Claim 31, wherein the anticholinergic agent is atropine, propantheline, emepronium, trospium, tolteridone, darifenacin, oxybutinin or hyoscine.

10

33. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a nitric oxide synthase ("NOS") antagonist.

34. Use as claimed in Claim 33, wherein the NOS antagonist is L-NAME.

15

35. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a prostaglandin modifier.

20

36. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a beta antagonist, a beta-2 antagonist or a beta-3 antagonist.

37. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a GABA agonist.

25

38. Use as claimed in Claim 37, wherein the GABA agonist is baclofen.

39. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a tricyclic antidepressant.

30

40. Use as claimed in Claim 39, wherein the tricyclic antidepressant is imipramine or amitriptyline.

41. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a noradrenaline and serotonin uptake inhibitor.
42. Use as claimed in Claim 41, wherein the uptake inhibitor is duloxetine.
- 5 43. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a serotonin agonist or antagonist.
44. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is an opioid analogue.
- 10 45. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a dopaminergic antagonist.
46. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a beta-antagonist, a beta-2 antagonist or a beta-3 antagonist.
- 15 47. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is glutamate or a related agonist.
- 20 48. Use as claimed in Claim 27 or Claim 28, wherein the smooth muscle contractant is a tachykinin antagonist.
49. Use as claimed in any one of Claims 27 to 48, wherein the medicament comprises an antacid.
- 25 50. Use as claimed in any one of Claims 1 to 49, wherein the smooth muscle tone modulator is present in the medicament in a concentration of from 0.01 to 40 wt %.
- 30 51. Use of a composition comprising a smooth muscle tone modulator and a therapeutically acceptable mucoadhesive vehicle in the manufacture of a

medicament for the topical treatment of oesophageal motility disorders and GORD.

52. Use as claimed in Claim 51, wherein the smooth muscle tone modulator is a smooth muscle relaxant and the medicament is for use in the topical treatment of oesophageal spasm, nutcracker oesophagus, non-specific oesophageal motility disorder, and other oesophageal body dysmotility syndromes.

53. Use as claimed in Claim 51, wherein the smooth muscle tone modulator is a smooth muscle relaxant and the medicament is for use in the topical treatment of achalasia and hypertensive LOS.

54. Use as claimed in Claim 51, wherein the smooth muscle tone modulator is a smooth muscle contractant and the medicament is for use in the topical treatment of GORD.

55. A method of treating oesophageal motility disorders and GORD comprising administering topically a pharmaceutically acceptable amount of a smooth muscle tone modulator to the upper GI tract.

56. A method of treating a condition selected from the group consisting of oesophageal spasm, nutcracker oesophagus, non-specific oesophageal motility disorder and other disorders of oesophageal dysmotility comprising administering topically a pharmaceutically acceptable amount of a smooth muscle relaxant to the upper GI tract.

57. A method of treating achalasia and hypertensive LOS comprising administering topically a pharmaceutically acceptable amount of a smooth muscle relaxant to the upper GI tract.

58. A method of treating GORD comprising administering topically a pharmaceutically acceptable amount of a smooth muscle contractant to the upper GI tract.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number
WO 02/062324 A3

(51) International Patent Classification⁷: A61K 31/00,
A61P 1/06

(21) International Application Number: PCT/GB02/00310

(22) International Filing Date: 24 January 2002 (24.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0102854.7 5 February 2001 (05.02.2001) GB
0102855.4 5 February 2001 (05.02.2001) GB
0102856.2 5 February 2001 (05.02.2001) GB

(71) Applicant and

(72) Inventor: KAMM, Michael, Albert [AU/GB]; 4
Willoughby Road, Hampstead, London NW3 1SA (GB).

(74) Agent: BURFORD, Anthony, F.; W. H. Beck, Greener &
Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ
(GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
14 November 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/062324 A3

(54) Title: A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-OESOPHAGEAL REFLUX DIS-
EASE

(57) Abstract: Smooth muscle one modulators are applied topically to treat oesophageal motility disorders and gastro-oesophageal
reflux disease. Topical application of the smooth muscle tone modulators reduces the risk of the unwanted side-effects observed
from oral or sublingual administration of the modulators.

INTERNATIONAL SEARCH REPORT

 Inten " I Application No
 PC, -- 02/00310

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/00 A61P1/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 33186 A (PHARMACIA SPA) 24 October 1996 (1996-10-24) abstract page 13, line 11 - line 20 page 14, line 10 - line 15 claims 1-15	4-7
X	DATABASE WPI Week 199823 Derwent Publications Ltd., London, GB; AN 1998-259547 XP002198121 & RU 2 091 067 C (MYSLITSKAYA, L.N.), 27 September 1997 (1997-09-27) abstract -/--	4-7

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

6 May 2002

Date of mailing of the international search report

02.09.02

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Taylor, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT, 02/00310

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FANG J.C. ET AL.: "Cholinergic blockade inhibits gastro-oesophageal reflux and transient lower oesophageal sphincter relaxation through a central mechanism" GUT, vol. 44, no. 5, 1999, pages 603-607, XP001069653 abstract page 605, Results ---	4-7
P,X	WO 01 42252 A (HOLMEN ANDERS ;OLSSON THOMAS (SE); ASTRAZENECA AB (SE); ELEBRING T) 14 June 2001 (2001-06-14) abstract page 2, line 14 - line 29 page 5, line 29 - line 30 claims 1-26 -----	4-7

INTERNATIONAL SEARCH REPORT

International application No.
CT/GB 02/00310

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 55-58
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 1-3, 15, 25, 28, 35, 44, 51
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

4-7

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3,15,25,28,35,44,51

Present claims 1-3 15, 25, 28, 35 and 51 relate to a product defined by reference to desirable characteristics or properties, namely

- "smooth muscle tone modifier" (claims 1 and 51);
- "mucoadhesive" (claims 2 and 51);
- "prostaglandin modifier" (claims 15 and 35);
- "cholinomimetic agent" (claim 25);
- "the medicament is used in a swallowable form that forms a raft that floats on the surface of the contents of the stomach" (claim 28);
- "an opioid analogue" (claim 44).

The claims cover all products having these characteristics or properties, whereas the application provides support within the meaning of Art. 6 PCT and/or disclosure within the meaning of Art. 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Art. 6 PCT). An attempt is made to define the products by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Furthermore, the expressions listed above are considered to be so unclear, vague and indefinite in themselves as to render a meaningful search impossible.

Claim 3, being dependent solely on unsearchable claims, also has not been searched.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the second medical use of smooth muscle relaxants, as defined in the remaining claims 4-14, 16-24, 26, 27, 29-34, 36-43, 45-50 and 52-54.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 4-7

The use of calcium channel blockers in the preparation of a medicament for the treatment of oesophageal motility disorders.

2. Claims: 4,5,8

The use of potassium channel openers in the preparation of a medicament for the treatment of oesophageal motility disorders.

3. Claims: 4,5,9,10

The use of NO donors in the preparation of a medicament for the treatment of oesophageal motility disorders.

4. Claims: 4,5,11,12,21,22,27,29,30,49,50,52-54

The use of adrenergic agonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

5. Claims: 4,5,13,27,29,36,49,50,52-54

The use of beta, beta-2 or beta-3 agonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

6. Claims: 4,5,14,27,29,45,49,50,52-54

The use of dopaminergic agonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

7. Claims: 4,5,16,27,29,37,38,49,50,52-54

The use of GABA antagonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

8. Claims: 4,5,17,47,49,50,52-54

The use of glutamate antagonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

disorders.

9. Claims: 4,5,18,48,49,50,52-54

The use of tachykinin antagonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

10. Claims: 4,5,19

The use of capsaicin, dicyclomine or flavoxate in the preparation of a medicament for the treatment of oesophageal motility disorders.

11. Claims: 4,5,20,27,29,31,32,49,50,52-54

The use of anticholinergic agents in the preparation of a medicament for the treatment of oesophageal motility disorders.

12. Claims: 4,5,23

The use of cholinergic / anticholinesterase agents in the preparation of a medicament for the treatment of oesophageal motility disorders.

13. Claims: 4,5,26

The use of bethanecol in the preparation of a medicament for the treatment of oesophageal motility disorders.

14. Claims: 27,29,33,34,49,50,52-54

The use of NOS antagonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

15. Claims: 27,29,39,40,49,50,52-54

The use of tricyclic antidepressants in the preparation of a medicament for the treatment of oesophageal motility disorders.

16. Claims: 27,29,41,42,49,50,52-54

The use of noradrenaline and serotonin uptake inhibitors in the preparation of a medicament for the treatment of

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

oesophageal motility disorders.

17. Claims: 27,29,43,49,50,52-54

The use of serotonin agonists or antagonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

18. Claims: 27,29,45,49,50,52-54

The use of dopaminergic antagonists in the preparation of a medicament for the treatment of oesophageal motility disorders.

INTERNATIONAL SEARCH REPORT

International Application No

PCT. 92/00310

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9633186	A	24-10-1996	WO 9633186 A1	24-10-1996
			EP 0766680 A1	09-04-1997
			JP 10502095 T	24-02-1998
RU 2091067	C	27-09-1997	RU 2091067 C1	27-09-1997
WO 0142252	A	14-06-2001	AU 2036401 A	18-06-2001
			WO 0142252 A1	14-06-2001